Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed/refractory non-Hodgkin lymphoma following CD34+-selected hematopoietic cell transplantation
- PMID: 12763934
- DOI: 10.1182/blood-2003-01-0095
Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed/refractory non-Hodgkin lymphoma following CD34+-selected hematopoietic cell transplantation
Abstract
We explored the feasibility and toxicity of administering escalating doses of anti-CD3/CD28 ex vivo costimulated T cells as a therapeutic adjunct for patients with relapsed, refractory, or chemotherapy-resistant, aggressive non-Hodgkin lymphoma (NHL) following high-dose chemotherapy and CD34+-selected hematopoietic cell transplantation (HCT). Sixteen patients had infusions on day 14 after HCT of autologous T cells that had been stimulated using beads coated with anti-CD3 and anti-CD28 monoclonal antibodies. At baseline, the subjects had severe quantitative and functional T-cell impairments. The culture procedure partially reversed impaired cytokine responsiveness in T cells in vitro and in vivo. Transient dose-dependent infusion toxicities were observed. There was a rapid reconstitution of lymphocytes; however, there were persistent defects in CD4 T cells. Most interestingly, 5 patients had a delayed lymphocytosis between day 30 and day 120 after HCT. Maximal clinical responses included 5 patients with a complete response (CR), 7 patients with a partial response (PR), and 4 patients with stable disease. At a median follow-up of 33 months (range, 26-60 months), 5 patients are alive with stable or relapsed disease and 3 patients remain in CR. In conclusion, this phase 1 trial demonstrates that adoptive transfer of autologous costimulated T cells (1) is feasible in heavily pretreated patients with advanced NHL, (2) is associated with a rapid recovery of lymphocyte counts, (3) reverses cytokine activation deficits in vitro, and (4) is associated with delayed lymphocytosis in a subset of patients.
Similar articles
-
Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.Eur J Haematol. 2007 Feb;78(2):93-101. doi: 10.1111/j.1600-0609.2006.00796.x. Eur J Haematol. 2007. PMID: 17313557 Clinical Trial.
-
Phase I trial of dacarbazine with cyclophosphamide, carmustine, etoposide, and autologous stem-cell transplantation in patients with lymphoma and multiple myeloma.J Clin Oncol. 1994 Sep;12(9):1890-901. doi: 10.1200/JCO.1994.12.9.1890. J Clin Oncol. 1994. PMID: 7916039 Clinical Trial.
-
BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients.Blood. 2011 Sep 22;118(12):3419-25. doi: 10.1182/blood-2011-04-351924. Epub 2011 Aug 3. Blood. 2011. PMID: 21816830 Clinical Trial.
-
Novel regimens prior to autologous stem cell transplantation for the management of adults with relapsed/refractory non-Hodgkin lymphoma and Hodgkin lymphoma: alternatives to BEAM conditioning.Leuk Lymphoma. 2016 Nov;57(11):2499-509. doi: 10.1080/10428194.2016.1185785. Epub 2016 May 31. Leuk Lymphoma. 2016. PMID: 27243412 Review.
-
Immune and Cell Therapy in Non-Hodgkin Lymphoma.Cancer J. 2020 May/Jun;26(3):269-277. doi: 10.1097/PPO.0000000000000445. Cancer J. 2020. PMID: 32496460 Review.
Cited by
-
Improving day-treatment services for adults with severe disabilities: a norm-referenced application of outcome management.J Appl Behav Anal. 2004 Fall;37(3):365-77. doi: 10.1901/jaba.2004.37-365. J Appl Behav Anal. 2004. PMID: 15529892 Free PMC article.
-
Treatment of metastatic non-small cell lung cancer with NY-ESO-1 specific TCR engineered-T cells in a phase I clinical trial: A case report.Oncol Lett. 2018 Dec;16(6):6998-7007. doi: 10.3892/ol.2018.9534. Epub 2018 Oct 1. Oncol Lett. 2018. PMID: 30546433 Free PMC article.
-
Interrogating Cellular Functions with Designer Janus Particles.Chem Mater. 2017 Feb 28;29:1448-1460. doi: 10.1021/acs.chemmater.6b05322. Epub 2017 Jan 20. Chem Mater. 2017. PMID: 31530969 Free PMC article.
-
Immunotherapy for pediatric cancer.Biol Blood Marrow Transplant. 2008 Jan;14(1 Suppl 1):33-43. doi: 10.1016/j.bbmt.2007.10.014. Biol Blood Marrow Transplant. 2008. PMID: 18162219 Free PMC article. Review.
-
Studies on regulation of IGF (insulin-like growth factor)-binding protein (IGFBP) 4 proteolysis by pregnancy-associated plasma protein-A (PAPP-A) in cells treated with phorbol ester.Biochem J. 2004 Apr 1;379(Pt 1):57-64. doi: 10.1042/BJ20030937. Biochem J. 2004. PMID: 14705967 Free PMC article.
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials